Qurient Study Shows CDK7 Inhibitor Q901 Enhances Cancer Drug Activity

Qurient Co., Ltd. announced the publication of a study in Science Advances demonstrating that its selective CDK7 inhibitor, Q901 (mocaciclib), significantly enhances the antitumor activity of TOP1 inhibitor-based antibody-drug conjugates.